TP53 was a predominant regulator and controlled multiple altered pathways in ccRCC (regulated 36% significantly altered pathways of ccRCC) and PRCC (regulated 9% significantly altered pathways of PRCC) subtype, especially for ccRCC. This evidence concerns the gene PRCC and nonpapillary renal cell carcinoma.